A Phase 1 interventional study of ECC4703 and Sulfasalazine in Non-alcoholic Fatty Liver Disease (NAFLD) and Dyslipidaemia, sponsored by Eccogene. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Eccogene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia — 8 open to participants now, 12 under way, 10 of them phase 3. Non-alcoholic Fatty Liver Disease · Australia.
Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, this one is the 49th largest by planned enrollment, is one of 2 that started in 2026, is one of 15 in phase 1, reaches primary completion later than 2 of the 11 other live ones, and was the 53rd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →8 of the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Australia, United States, France and 5 more countries
Ages 18–75
GlaxoSmithKline · Sites in Australia, United States, Canada and 6 more countries
Ages 18–75
Eli Lilly and Company · Sites in Australia, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Australia, United States, Argentina and 20 more countries
Ages 18–80
Hoffmann-La Roche · Sites in Australia, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 23 · Phase 3 17
First in 2014; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 264 across the 54 interventional studies. Of the 40 that completed or were terminated, 24 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 54 have an industry lead sponsor. The 10 most frequent:
Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Eccogene has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-alcoholic Fatty Liver Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07726368EccogeneStudy of ECC4703 With Sulfasalazine and Pitavastatin | 2026-12 |
| NCT07873229EccogeneDDI Study of ECC0509 With Metformin, Midazolam, and Caffeine | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide.
ECC4703 is a potential new treatment for non-alcoholic fatty liver disease.
The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 participants will receive ECC4703 and sulfasalazine.
Drug: ECC4703 · Drug: Sulfasalazine
Cohort 2 participants will receive ECC4703 and pitavastatin.
Drug: ECC4703 · Drug: Pitavastatin
ECC4703 will be administered orally.
Sulfasalazine will be administered orally.
Pitavastatin will be administered orally.
Maximum plasma concentration of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Time to maximum plasma concentration of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Area under the drug concentration-time curve of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Clearance of sulfasalazine in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Maximum plasma concentration of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Time to maximum plasma concentration of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Area under the drug concentration-time curve of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Clearance of pitavastatin in the blood of participants who have taken ECC4703 (as part of called pharmacokinetic or 'PK' testing)
Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 3, 4, 9, 10, 11 and 12
Number of participants with Adverse Events (AEs), as assessed by a 5-point scale, CTCAE v5.0
Adverse event monitoring includes measuring the frequency, severity and relationship of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) leading to treatment or study discontinuation. Severity of adverse events will be characterised from 1 (mild) to 5 (death).
Time frame: From baseline to follow-up visit (on Day 19).
Change from Baseline in blood pressure, measured using a sphygmomanometer via a cuff on the arm
Time frame: From baseline to follow-up visit (on Day 19).
Change from Baseline in heart rate, measured in beats-per-minute by a vital signs machine
Time frame: From Baseline to follow-up visit (on Day 19).
Change from Baseline in respiratory rate, measured in breaths-per-minute manually via a 60-second count
Time frame: From Baseline to follow-up visit (on Day 19).
Change from Baseline in body temperature in degrees Celsius, measured using a thermometer
Time frame: From Baseline to follow-up visit (on Day 19).
Changes from Baseline in Clinical Laboratory Parameters including, but not limited to, haematology and blood chemistry.
Blood samples will be collected. All safety laboratory assessments will be assessed by a certified local laboratory, using that laboratory's normal ranges. Any clinically significant changes will be recorded as Adverse Event (AE). The severity of each AE (and SAE or Serious Adverse Event) will be graded using a 5-point scale
Time frame: From baseline to follow-up visit (on Day 19)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ECC4703 · Sulfasalazine · Pitavastatin
Non-alcoholic Fatty Liver Disease →
Eccogene